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Background: In patients with chronic hepatitis C (CHC), obesity is involved in the pathogenesis of insulin
resistance, fatty liver disease and progression of fibrosis. The objective of this study was to compare a
normoglucidic low-calorie diet (NGLCD) with a low-fat diet (LFD) among participants with CHC. Aimed to measure
the impact of dietary changes in reduction of insulin resistance, obesity but also in steatosis and fibrosis.
Methods: Randomized, controlled trial in three medical centers with assessments at baseline, 6 months and 12 months.
Participants were patients over 35 years with chronic hepatitis C (n = 120) with BMI over 25 kg/m2. We evaluated the
effects of NGLCD vs. LFD in weight management and metabolic improvement. The primary endpoint was to measure
the impact of dietary changes through nutritional intervention in reversibility of insulin resistance, obesity, steatosis,
and fibrosis. We performed anthropometric measurements, fasting glucose profile, serum lipids, liver profile, blood
count at baseline, 6 and 12 months. Steatosis was evaluated using ultrasonographic criteria. Liver fibrosis was
non-invasively assessed.
Results: After 6 and 12 months of intervention, both groups had a significant decrease in caloric consumption.
At 6 months, weight loss was greater in the NGLCD group (−5.02 ± 3.43 kg vs. −4.1 ± 2.6 kg; p = 0.002) compared
to the LFD group. At 1-year, however, weight loss was similar in both groups (−3.9 ± 3.3 kg vs. −3.1 ± 2.6 kg; p = 0.139).
At 12 months, fasting plasma glucose, fasting plasma insulin, and HOMA-IR had significant improvements in both
groups. With both diets aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl
transpeptidase (GGT) decreased with significant differences; also there were significant improvements in AST/ALT ratio,
Forns fibrosis index. The two diets were associated with reduction of both the prevalence and the severity of steatosis
(all p < 0.001). At 12 months, total cholesterol, HDL-cholesterol, triglycerides improved in both groups (all p < 0.05).
Conclusions: The present study establishes the benefits of low-calorie diet and low-fat diet in management of patients
with hepatitis C regarding improvement of insulin resistance, steatosis and also fibrosis.
Overweight or obese patients with CHC undergoing a lifestyle intervention (specific dietary intervention and physical
activity) for 1-year had significant improvements in body weight, lipid and hepatic profile.
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The prevalence of hepatitis C virus (HCV) infection world-
wide is estimated at 3% [1]. World Health Organization
estimates that the prevalence of HCV in Europe is 1% [1].
In Romania, statistics show that there are 1 million people
(4.5% of the population) infected with HCV [2].
Chronic hepatitis C (CHC) can be considered a meta-
bolic liver disease which implies: insulin resistance (IR),
increased prevalence of impaired glucose tolerance or
type 2 diabetes mellitus (T2DM), changes in lipid me-
tabolism, and a high prevalence of steatosis [3].
As obesity is involved in the pathogenesis of hepatic
steatosis and fibrosis progression, one of the important
objectives of nutrition management is weight control.
Methods
Trial design
This multicenter, randomized controlled trial was conducted
from September 2007 to December 2010.
Participants
Participants were recruited from three hospitals from
Bucharest, Romania. The inclusion criteria were: age over
35 years, BMI over 25 kg/m2 diagnosis of chronic hepatitis
C (CHC infection was defined by the presence of anti-
HCV antibodies for a least 6 months and a positive
HCV-viremia).
The exclusion criteria were: patients with other eti-
ology of chronic liver disease, hepatitis B, autoimmune
liver disease, hemochromatosis, HIV infection, patients
with history of hepatotoxic or steatosis-inducing drug
use, currently on interferon treatment or during the last
12 months, patients having an alcohol consumption of
more than 20 g/day for women and 30 g/day for men,
history of pancreatitis.
Study setting
The study was conducted in Bucharest, the most import-
ant commercial urban setting of Romania, with a popu-
lation of 2 million and an estimated CHC rate of 3.35%
in adults (data as of 2007).
Trial overview
The DIADIPOHEP (Adipocitokynes, link between virus
C hepatitis and type 2 diabetes mellitus)) study was
approved by the Romanian National Authority for Scien-
tific Research. Written informed consent was obtained
from all participants.
Enrollment began in September 2007 and ended in
December 2010. Participants were recruited from three
hospitals. Eligibility was established through a screening
visit that included a physical examination and a review
of the patient's medical history. Following completion of
baseline assessments, participants were randomized to anormoglucidic low-calorie diet (NGLCD) group, or to a
low-fat diet (LFD) group, both with a lifestlye manage-
ment program.
Outcome measures
The primary endpoint was to measure the impact of dietary
changes in reduction of insulin resistance as well as hepatic
steatosis and fibrosis through nutritional intervention. Sec-
ondary endpoints included changes in weight, lipid profile
(total cholesterol, LDL-cholesterol, HDL-cholesterol and
triglycerides), blood pressure (systolic and diastolic), hep-
atic profile, and renal function (estimated glomerular fil-
tration rate [eGFR]).
Assessments
We performed anthropometric measurements (weight,
height, BMI (body mass index), waist circumference,
waist to hip ratio (WHR)) every month.
Body mass index (BMI) was calculated as weight (in
kilograms) divided by height (in meters squared). Based
on the World Health Organization classification, over-
weight was defined as BMI between 25 and 29.9 kg/m2,
and obesity was defined as BMI over 30 kg/m2 [4]. We
also measured waist circumference (in centimeters) at the
mid-point of the distance between the 12th rib and iliac
crest and hip circumference at the greater trochanters
with the legs brought together.
Arterial blood pressure was measured three times at
the end of the physical examination with the subject in
the sitting position. Participants whose average blood
pressure levels were greater or equal to 140/90 mmHg
or receiving antihypertensive medication were classified
as hypertensive subjects [5].
Laboratory assays
Fasting blood samples were drawn between 7:00 a.m.
and 10:00 a.m.
The biochemical analyses, including fasting serum lipids
(total cholesterol (TC), triglyceride (TG), high-density
lipoprotein-cholesterol (HDL-C)), glucose profile (fasting
plasma glucose (FPG), fasting plasma insulin (FPI),
glycated hemoglobin (HbA1c)), liver function tests
(aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), gamma-glutamyl transpeptidase (GGT),
alkaline phosphatase, bilirubin, albumin, total protein,
International Normalized Ratio (INR)), were performed
at baseline, 6 and 12 months with commercially available
kits from Roche-Hitachi Systems which were analyzed on
a Hitachi 917 autoanalyser. Low-density lipoprotein chol-
esterol (LDL-C) was calculated using the Friedwald for-
mula (LDL-C = TC −TG/5 +HDL-C) [6].
Serum C-peptide was measured through an electro-
chemiluminescence immunoassay (Modular Analytics,
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cients of variation of 4.5% and 6.9%, respectively.
Insulin concentration was determined through RIA
(Abbott Axsym System, Chicago IL), with intra- and
interassay coefficients of variation of 4.5% and 6.9%,
respectively.
FPI and C peptide were measured at baseline and 12
months. Insulin resistance (IR) was determined using
Homeostasis model assessment (HOMA-IR)(fasting in-
sulin level (mUI/l)x fasting glucose level (mg/dl)/405 [4];
a HOMA-IR index value of more than 2.0 was consid-
ered as the criteria of insulin resistance [7].
The oral glucose tolerance test (OGTT) was performed
in patients with HbA1c higher than 5.5%. For OGTT, a
glucose load equivalent to 75 g anhydrous glucose was
given in a total water volume of 250 –300 ml [8]. The glu-
cose drink was consumed over 5 min. Timing for the rest
of the test started at the beginning of ingestion. A further
blood sample was collected 2 h after the glucose load in
order to measure the glucose concentration. Diabetes
diagnostic was made according to ADA 2003 criteria [9].
The definition of the metabolic syndrome (MetS) was
based on the IDF criteria (central obesity defined as waist
circumference over 94 cm in men, over 80 cm in women
or BMI over 30 kg/m2 plus any two of the following
factors: 1. triglycerides (TG) ≥1.695 mmol/l (150 mg/dl)
or treatment; 2. high density lipoprotein-cholesterol
(HDL-C) lower than 40 mg/dl in men, 50 mg/dl in
women or treatment; 3. blood pressure ≥130/85 mmHg
or medication; 4. fasting blood glucose ≥ 5.6 mmol/l
(100 mg/dl) or medication for diabetes [10].
Liver fibrosis was non-invasively assessed using the
Forns fibrosis index (FI) [11]; a value < 4.2 excludes liver
fibrosis and a value > 6.9 is a predictor for significant
fibrosis. Forns fibrosis index was calculated according
to formula: 7.811–3.131 ln[platelet count (109/l)] + 0.781
ln[gamma-glutamyl transpeptidase (GGT) (UI/l)] + 3.467
ln[age (years)] − 0.014[cholesterol (mg/dl)]. The presence
of significant fibrosis was predicted with a 96% negative
predictive value (NPV) and 66% positive predictive value
(PPV) [11].
The AST to platelet ratio index (APRI) was calculated
by dividing the AST level (UI/l), expressed as the num-
ber of times above the upper limit of normal (ULN), by
the platelet count (109/l): AST (/ULN) × 100/platelet
count (109/l) [12]. APRI is simpler to use than most of
the other indices with similar performance to that of the
Fibrotest (FT) and the Forns fibrosis index. This index
has been validated in HCV patients [12]. An 86% NPV
and an 88% PPV were reported to predict the presence
of significant fibrosis and a 98% NPV and a 57% PPV
were reported to predict the presence of cirrhosis [12].
Hepatic steatosis (HS) was evaluated using ultrasono-
graphic criteria. Hepatic ultrasound is a sensitive procedurefor detecting liver fat (sensitivity 91–100, specificity
93–100) [13]. The severity of echogenicity was graded
as follows: grade 0, normal echogenicity; grade 1, slight,
diffuse increase in fine echoes in liver parenchyma with
normal visualization of diaphragm and intrahepatic vessel
borders; grade 2, moderate, diffuse increase in fine echoes
with slightly impaired visualization of intrahepatic vessels
and diaphragm; grade 3, marked increase in fine echoes
with poor or nonvisualization of the intrahepatic vessel
borders, diaphragm, and posterior right lobe of the liver.
Estimated glomerular filtration rate (eGFR) was made
according to CKD-EPI equation [14]. The CKD-EPI
equation, expressed as a single equation, is: GFR = 141
X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018
[if female] X 1.159 [if black].
Randomization
Independently done computer randomization was used
to allocate numbers and divide the patients into two
groups. Randomization was done by block design to ensure
equal numbers in each group for every 4 subjects recruited.
Diet
All patients received nutrition counseling (NGLCD or
LFD) in individual sessions every week in the first 6 months
and every month thereafter until 12 months, with biological
reevaluation at 6 and 12 months. All patients were required
to submit a food journal at the baseline visit (before group
allocation), as well as subsequent journals prior to the
6 month, 12 month, and each monthly visit. The food
journal covers a 4 day period that includes 2 working
days and 2 free days/weekend. Foods were measured
using standard measuring cups and spoons and weight
for 100 g; the input accuracy of the food journals was
confirmed by using food-frequency questionnaires.
No supplements were allowed in this period. Patients
who missed more than 30% of dietitian appointments or
did not complete the food journals were considered
noncompliant and were excluded from final analysis.
Macronutrient intake was calculated using the
United States Department of Agriculture's food data-
base (National Nutrient Database for Standard Reference,
Release 16–1 and 17, Release dates July 2003 and 2004,
Beltsville, MD) [15].
Subjects were required to limit alcohol intake to
<20 g/week during the intervention period. Alcohol
intake was averaged and recorded as grams per week.
Normoglucidic low-calorie diet
Dietitian doctors instructed participants to follow a diet
comprising approximately 50-60% of daily caloric intake
from carbohydrates [16], 25-35% of total calories from
fat (less than 7% of total calories from saturated fat, less
than 1% trans fatty acids, 10% monounsaturated fatty
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less than 300 mg cholesterol per day), proteins 15% of
total calories (1.0 to 1.2 g/kg/day) [17], and <5% of caloric
intake from simple sugars. Nutrient-rich choices that
included whole grains, vegetables and fruit were prioritized.
NGLCD was defined as a normoglucidic, normolipidic,
normoproteic, low-calorie diet (100–500 kcal less than esti-
mated energy needs).
Low-fat diet
Restriction of fat intake to 20% of total daily energy up-
take with avoidance of trans-fat and saturated fat, up to
20% of the total calories from proteins and 60-65% car-
bohydrates. Further recommendation included increasing
fibre uptake to 30 g per day, and avoiding liquid mono-
and disaccharides. Moreover, patients were advised to
consume at least 250 to 300 g of fruits, 125 to 150 g of
vegetables, and 25 to 50 g of walnuts per day; in addition,
they were also encouraged to consume 400 g of whole
grains (rice, maize, and wheat) daily and to increase their
consumption of olive oil. Compared with normoglucidic
low-calorie diet, low-fat diet was defined by a low intake
of fat (up to 20% of caloric intake), increased carbohydrate
intake up to 60-65% of daily caloric intake, increased fiber
intake (30 g/day), and protein intake up to 20%.
Physical activity
A healthy lifestyle includes regular physical activity (PA).
Regular physical activity included 30 minutes of moderate
intensity physical activities (e.g. brisk walking, jogging,
cycling) for 3–7 days a week, recommended for persons
with hepatitis C virus infection without advanced cir-
rhosis or other metabolic complications [18].
Energy needs
A high-energy diet is normally recommended for HCV-
infected persons [19,20]. Measured energy needs of pa-
tients with HCV infection, even in the absence of cirrhosis,
are on average higher per unit of lean body mass than
the needs of healthy individuals [21]. The following pro-
vides two reasonable estimates of energy needs for patients
undergoing physiological stress, such as those with infec-
tion: 25 to 40 kcal/kg, based on dry weight or an adjusted
ideal weight [22] or add 20% to 40% to basal energy ex-
penditure (BEE) using the Harris-Benedict equation [23].
In patients with overweight or obesity, the energy in-
take was individualized to be 100–500 kcal less than
estimated energy needs because we designed it to in-
duce at least a 5-10% weight loss at 6 months and to
maintain this weight loss in the subsequent 6 months.
Statistics
Results for continuous normally distributed data were
expressed as mean ± standard deviations (SD). Tests ofnormality used were Kolmogorov-Smirnov with a Lilliefors
significance correction and Shapiro-Wilk statistic. The
comparison of mean value at baseline, 6 months and 12
months was performed with paired t-test. For continuous
nonnormal distribution we used Wilcoxon's rank-sum
tests, and data were reported as median ± interquartile
ranges. Pearson's χ2 tests were used to compare changes
in continuous variables from beginning categorical base-
line characteristics. Wilcoxon's rank-sum tests were also
used to compare changes in continuous variables from
baseline to the 12 month. P-value less than 0.05 was con-
sidered significant. All statistical analyses were performed
using SPSS 19 (copyright IBM).
The primary analysis was intention-to-treat and involved
all patients who were randomly assigned [24]. Two patients
in the NGLCD group and eight patients in LFD groups
were lost to follow up; thus data from 110 patients were
available for the intention-to-treat analysis.
Results
The flow chart for study participants is presented in
Figure 1 [25]. The completion rate was 91.6%; 10 of
the 120 subjects (8.3%) participating at baseline did not
complete the 1-year intervention: 2/60 (3.3%) in the
NGLCD group and 8/60 (8.3%) in the LFD group. The
dropout rate in the LFD group was significantly greater
than that in the NGLCD (p = 0.047). At baseline, in both
groups, there were no statistically significant differences
between patients who completed the study and those who
dropped out.
The baseline characteristics of participants who com-
pleted the 1-year intervention are presented in Table 1;
participants were similar in sex distribution, smoking,
glycemic state, hypertension, dyslipidemia (Table 1). There
were no significant differences between the groups (data
not shown) for demographic characteristics, marital sta-
tus, environment, occupation. In both groups, compared
with women, men had a higher mean baseline BMI (mean
difference 1.96 kg/m2 [95% CI 0.13, 3.79]) in NGLCD
group and 2.1 kg/m2 [95% CI 0.33, 4.06]) in LFD group.
All patients were affected by genotype 1.
The average age was 54.3 ± 8.6 years in NGLCD group
and 54.2 ± 9.3 years in LFD group (p = 0.51).
Overweight was present at baseline in 60.3% (n = 35)
patients in NGLCD group and in 55.8% (n = 29) patients
in LFD group; the other patients had obesity (p = 0.53
between groups). Overweight was present at 12-months
in 55.2% (n = 32) patients in NGLCD group and in 57.7%
(n = 30) patients in LFD group; obesity was present in
20.7% (n = 12) patients in NGLCD group and in 23.1%
(n = 12) patients in LFD group.
The prevalence of MetS at baseline was similar between
groups (61.5% in NGLCD (n = 36) vs. 61.5% in LFD
(n = 32), p = 0.55) but higher in men from LFD group
Figure 1 Participant flow diagram.
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45.2% (n = 14), p = 0.003).
Kilocalories and macronutrients
At baseline, analysis of the 4-day food journal showed
that calorie intake of the two groups was not significantly
different (2247 ± 160 Kcal/day vs. 2213 ± 157 Kcal/day in
the NGLCD and LFD, p = 0.261). The results were similarTable 1 Demografic and clinical characteristics at baseline
NGLCD (n = 58)
Gender M (n = 26)
Age (years) 52.5 ± 7.1
BMI (kg/m2) 30.6 ± 4.4
WC (cm) 95.6 ± 15.4
Obesity (number, %) 19 (73.1%)
Hypertriglyceridemia (number, %) 18 (69.2%)
HypoHDL-cholesterolemia (number, %) 18 (69.2%)
Cigarette smoking (number, %) 10 (38.5%)
Diabetes (number, %) 11 (42.3%)
IGT (number, %) 1 (3.8%)
IFG (number, %) 5 (19.2%)
Normal glucose tolerance (number, %) 14 (53.8%)
Hypertension (number, %) 15 (57.7%)
MetS (number, %) 18 (69.9%)
All p > 0.05 except *, p = 0.036; **, p = 0.022; ***, p = 0.003; Values are expressed as
mass index, WC waist circumference, HDL high density lipoproteins, IGT impaired glfor the baseline protein (16.2 ± 1.6% vs. 16.3 ± 1.6%,
p = 0.506), lipid (33.9 ± 3.52% vs. 33.2 ± 3.51%, p = 0.1)
and carbohydrate intake (49.8 ± 3.4% vs. 50.2 ± 3.3%,
p = 0.8) in the NGLCD and LFD group, respectively.
Significant reduction in carbohydrate, protein and
lipid intake was observed in the NGLCD group both at
6 months and 12 months (all p < 0.001) (Table 2). In LFD
group we observed a significant reduction of calories andLFD (n = 52)
F (n = 32) M (n = 21) F (n = 31)
55.4 ± 9.7 52 ± 8.4 54.9 ± 10.1
29.6 ± 2.3* 30.7 ± 4.2 28.5 ± 2.4**
91.5 ± 12.2 98 ± 12.4 89.02 ± 9.8
24 (75%) 16 (76.2%) 22 (71%)
15 (46.9%) 17 (81%) 17 (54.8%)
19 (59.4%) 17 (81%) 15 (48.4%)
13 (40.6%) 7 (33.3%) 11 (35.5%)
7 (21.9%) 9 (42.9%) 6 (19.4%)
4 (12.5%) 5 (23.8%) 2 (6.5%)
2 (6.3%) 1 (4.8%) 6 (19.4%)
21 (65.6%) 11 (52.4%) 19 (61.3%)
13 (40.6%) 11 (52.4%) 19 (61.3%)
18 (56.3%) 18 (85.7%) 14 (45.2%)***
mean ± SD, NGLCD normoglucidic low-calorie diet, LFD low-fat diet, BMI body
ucose tolerance, IFG impaired fasting glucose, MetS metabolic syndrome.
Table 2 Kilocalories and macronutrients, comparison at baseline and after 6 and 12 months
NGLCD LFD
Baseline 6 months p0-6 12 months p0-12 Baseline 6 months p0-6 12 months p0-12
Kcalories 2247.9 ± 160.3 1909.8 ± 251.3 0.001 1842.8 ± 255.1 0.0001 22213.6 ± 157.7 1900.5 ± 226.7 0.0001 1845.2 ± 240.8 0.001
Protein (g) 91.3 ± 10.1 70.6 ± 11 0.0001 70.7 ± 11.8 0.0001 91 ± 10 90.9 ± 18.1 0.954 90.6 ± 16.8 0.861
Protein (%) 16.2 ± 1.6 14.8 ± 1.3 0.001 15.3 ± 1 0.0001 16.4 ± 1.6 19.9 ± 1.5 0.0001 20 ± 1.3 0.0001
Carbohydrate (g) 280.2 ± 30 265 ± 38.7 0.001 251.6 ± 40.4 0.0001 278.7 ± 32.2 285.2 ± 38.5 0.293 274.8 ± 36.6 0.513
Carbohydrate (%) 49.8 ± 3.4 55.3 ± 2.2 0.001 54.4 ± 2.5 0.0001 50.2 ± 3.3 60.1 ± 1.6 0.032 59.7 ± 1.3 0.0001
Lipid (g) 84.6 ± 10.3 63.5 ± 9.4 0.001 61.4 ± 8.1 0.0001 81.6 ± 1.2 44.6 ± 8.8 0.0001 43.3 ± 7.04 0.0001
Lipid (%) 33.9 ± 3.5 29.9 ± 2.4 0.0001 30.1 ± 2.9 0.0001 33.2 ± 3.5 19.6 ± 1.8 0.0001 20.2 ± 1 0.0001
Values are expressed as mean ± SD.
NGLCD normoglucidic low-calorie diet, LFD low-fat diet.
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intake during the intervention period (all p < 0.001 at 12
months) (Table 2).
After 6 and 12 months of intervention, both groups
had a significant decrease in caloric consumption (Table 2),
without differences between groups (p = 0.839 at 6 months,
and p = 0.96 at 12 months); at 12 months, fat consumption
in LFD patients was significantly lower (43.3 ± 7.04 g/day
vs. 61.4 ± 8.1 g/day).
Weight loss
At 6 months, weight loss was greater in the NGLCD
group (−5.02 [95% CI −5.9, -4.1]kg vs. −4.1 [95% CI −4.8,
-3.3]kg; p = 0.002) compared to the LFD group. At 1-year,
however, weight loss was similar in both groups (−3.9
[95% CI −4.8, -3.1]kg vs. −3.1 [95% CI −3.8, -2.3]kg;
p = 0.139). Most of the weight loss occurred in the first 6
months. After 12 months, patients slowly regained weight
after no longer being under observation on a regular basis.
We also found no significant sex differences for changes
in weight. A total of 18 patients in LFD group (34.6%) and
21 patients in NGLCD group (36.2%) continued to loseTable 3 Metabolic syndrome parameters
NGLCD
Baseline 12 months Mean change
WC (cm) 92.7 ± 13.6 89.5 ± 11.9 −3.3 ± 3.6 [−4.3
BMI (kg/m2) 29.4 ± 3.5 28.9 ± 3.6 −1.4 ± 1.1 [−1.7
Weight (kg) 84.07 ± 13.2 80.09 ± 13.8 −3.9 ± 3.3 [−4.8
Triglycerides (mg/dl) 157.4 ± 50.8 128.5 ± 31 −28.9 ± 5.09 [−
HDL-cholesterol (mg/dl) 42.7 ± 11.3 46 ± 10.2 3.3 ± 3.8 [4.3-2.3
FPG (mg/dl) 104.1 ± 27.9 96.9 ± 19.7 −7.2 ± 11.2 [−1
Cholesterol (mg/dl) 212.4 ± 40.4 190.2 ±20.2 −22.1 ± 28.6 [−
SBP (mmHg) 130.8 ± 11.2 125.9 ± 12.4 −4.8 ± 8.7 [−6.9
DBP (mmHg) 78.8 ±8.04 76.1 ± 8.6 −2.6 ± 10.6 [−5
Values are means ± SD; for mean change the results were expressed as means ± SD
NGLCD normoglucidic low-calorie diet, LFD low-fat diet, WC waist circumference, BM
SBP systolic blood pressure, DBP diastolic blood pressure.
All p < 0.005 for within group change from baseline to 12 months; All p >0.05 for dweight from 6 months to 1 year. At 1 year, 29.3% (n = 17)
patients in NGLCD group and 30.8% (n = 16) patients in
LFD group had lost between 5-10% of their initial body
weight; 10.3% (n = 6) patients in NGLCD group and 1.9%
(n = 1) patients in LFD group lost over 10% of their initial
weight (p = 0.33).
There were no significant differences between the groups
in body weight changes, BMI, waist circumferences at
12 months (Table 3).Physical activity
Before the start of the study all patients were sedentary,
not involved in any form of regular exercise (in NGLCD,
PA was 28.7 ± 18.7 min/week, in LFD, PA was 29.5 ±
19.3 min/week).
The degree of PA increased in the first 6 months in
both groups statistically significant; even if in the next
6 months PA decreased, the difference between baseline
and 12-months remained significant in both groups (for
NGLCD the difference was 56.5 min/week [95% CI, 46.4,
66.6] and 39 min/week [95% CI 28.7, 49.3] for LFD.LFD
Baseline 12 months Mean change
, -2.3] 92.4 ± 11.7 89 ± 10.6 −3.4 ± 3.1 [−6.7, -0.96]
, -1.1] 29.4 ± 3.4 28.3 ± 3.4 −1.1 ± 0.9 [−1.3, -0.8]
, -3.1] 83 ± 11.1 79.8 ± 11.5 −3.1 ± 2.6 [−3.8, -2.3]
39.1, -18.8] 164.6 ± 47.8 134.1 ± 32.3 −30.4 ± 38.7 [−41.2, -19.7]
] 42.3 ± 10.3 46.7 ± 8.9 4.4 ± 4.03 [3.3, 5.5]
0.2, -4.2] 103.7 ± 29.2 96.5 ± 19.1 −7.2 ± 13.1 [−10.8, -3.5]
29.5, -14.7] 209.1 ± 37 185 ± 16 −24.1 ± 27.5 [−31.8, -16.4]
,-2.7] 143.7 ± 12.2 129.4 ± 11.2 −4.9 ± 6.1 [−6.5, -3.3]
.2,-0.06] 84.8 ± 9.7 76.7 ± 10.3 −3.8 ± 11.1 [−6.7, -0.96]
and 95% confidence intervals.
I body mass index, HDL high density lipoproteins, FPG fasting plasma glucose,
ifference between groups at baseline and 12 months.
Table 4 Glucose metabolism parameters
NGLCD LFD
Baseline 12 months Mean change Baseline 12 months Mean change
FPG (mg/dl) 104.1 ± 27.9 96.9 ± 19.7 −7.2 ± 11.2 [−10.2, - 4.2] 103.7 ± 29.2 96.5 ± 19.1 −7.2 ± 13.1* [−10.8, -3.5]
FPI (μU/ml) 14.2 (11.5-21.8) 9.1 (6.2-16.9) −7.6 ± 11.5* [−10.7, -4.6] 12.8 (8.7-18.8) 9.15 (6.06-17.08) −5.2 ± 9.2* [−7.8, -2.6]
HOMA-IR 3.33 (2.3-5.9) 1.99 (1.45-4.04) −2.4 ± 4.1 * [−3.5, -1.3] 3.06 (1.93-5.11) 2.04 (1.3-4.4) −1.8 ± 3.9* [−2.9, -0.7]
C Peptide (ng/ml) 2.31 (2.01-2.8) 2.34 (2.08-2.9) −0.03-0.2 ** [−0.09, -0.03] 2.4 (2.07-2.97) 2.41 (2.1-3.1) −0.002 ± 0.2*** [−0.004, 0.01]
HbA1c (%) 5.7 ± 0.7 5.6 ± 0.7 −0.11 ± 0.3 * [−0.02, -0.2] 5.6 ± 0.5 5.5 ± 0.5 −0.09 ± 0.2* [−0.06, 0.05]
Values are means ± SD; for variables abnormally distributed we used median ± interquartile ranges (25th and 75th percentiles).
All p >0.05 for difference between groups at baseline and 12 months; *, p < 0.05 for mean change baseline, 12 months; **, p = 0.295; ***, p = 0.925.
NGLCD normoglucidic low-calorie diet, LFD low-fat diet, FPG fasting plasma glucose, FPI fasting plasma insulin, HOMA-IR homeostasis model assessment of insulin
resistance, HbA1c glycosylated hemoglobin.
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found only at the 12-months visit, when patients in the
NGLCD group continued to be more active (16.7 min/week
[95% CI 1.8, 31.5]).Effect of diet programs on insulin resistance
In NGLCD group, after the 12-month intervention we have
seen reductions of 5.5% (95% CI 3.4, 7.6) in FPG and of
27.4% (95% CI 20.3, 34.5) in FPI; in LFD group we also
observed a reduction of 5.2% (CI95% 2.9, 7.4) for FPG and
of 21.6% (95% CI 15.3, 28) for FPI, respectively. Pairwise
analyses test showed significant differences in changes of
FPG and FPI for the two groups (Table 4).
Insulin resistance determined through HOMA-IR im-
proved by 31.5% (95% CI 24.6, 38.5) in the NGLCD group;
HOMA-IR improved also in the LFD group (25.7% (CI95%
19.3, 32.1) (p = 0.219 between groups).
There were no significant differences in the 12-month
percentage changes in FPG, FPI, C peptide, homeostasis
model assessment for insulin resistance and homeostasis
model assessment for β-cell function, between groups. After
adjustment for body weight lost, HOMA-IR showed anTable 5 Parameters for hepatic function
NGLCD
Baseline 12 months Mean change
AST (IU/l) 48 (22–65.5) 40.5 (24.6-60.7) −6.2 ± 18.2* [−11,1,-1
ALT (IU/l) 57.5 (22–78) 42 (27.3-68) −10.6 ± 19.8* [−15.9,
GGT (IU/l) 46.5 (29–67.5) 39.5 (23.7-55) −9 ± 16 * [−13.2, -4.8
Albumin (g/dl) 4.3 ± 0.3 4.3 ± 0.3 0.06 ± 0.3 ** [−0.01,-
AST/ALT 0.95 ± 0.37 0.96 ± 0.26 0.01-0.3 *** [−0.07,-0
APRI 0.47 (0.3-0.82) 0.45 (0.27-0.69) −0.1 ± 0.27* [−0.17, -
FI 5.5 ± 1.1 5.3 ± 1.1 −0.2 ± 0.35* [−0.29, -
Values are means ± SD; for variables abnormally distributed we used median ± inter
All p >0.05 for difference between groups at baseline and 12 months; *, p < 0.05
12 months; **, p = 0.295; ***, p = 0.925; ##, p = 0.539; ###, p = 0.108.
NGLCD normoglucidic low-calorie diet, LFD low-fat diet, AST aspartate aminotransf
APRI AST to platelet ratio index, FI Forns fibrosis index.improvement with both diets (p = 0.026, respectively
p = 0.03).Effects of diet programs on hepatic profile
The liver function tests at baseline and after 12 months
for NGLCD and LFD groups are presented in Table 5.
With both diets AST, ALT, GGT decreased with sig-
nificant differences; also AST/ALT ratio, APRI score and
Forns index had significant improvements. Albumin and
bilirubin levels were not significantly changed (Table 5).
In order to assess the effects of weight loss on liver
function parameters patients were stratified according to
degree of weight loss (weight gain, 1-5% weight loss,
5-10% weight loss, and more than 10% weight loss). Both
diets proved to be efficacious in the improvement of liver
function parameters.In NGLCD patients group
In patients with less than 5% loss of baseline weight
(n = 30) (−2.1 kg [95% CI −2.5, -1.75]) there was an im-
provement of ALT levels (−15.1 [95% CI −22.8, - 7.5]),
GGT levels (−6.4 [95% CI [−10.9, -1.9]), AST/ALT ratioLFD
Baseline 12 months Mean change
.4] 58 (29.5-85.7) 47.5 (29–62) −8.7 ± 21.6# [−14.8, -2.7]
-5.4] 67 (41.2-102) 46 (33–67.7) −11.8 ± 32.2# [−20.8, -2.8]
] 62 (45–76) 42 (35–61.5) −12.1 ± 12.4# [−15.6, -8.6]
0.14] 4.2 ± 0.4 4.2 ± 0.3 0.06 ± 0.3## [−0.02, 0.15]
.09] 0.89 ± 0.31 0.92 ± 0.2 0.02 ± 0.32# [−.06, 0.12]
0.03] 0.73 (0.31-0.93) 0.53 (0.28-0.71) −0.13 ± 0.32### [−0.2, -0.1]
0.1] 5.5 ± 1.3 5.3 ± 1.3 −0.2 ± 0.31# [−0.3, -0.1]
quartile ranges (25th and 75th percentiles).
for mean change baseline, 12 months; #, p < 0.05 for mean change baseline,
erase, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase,
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[(95% CI, -0.005, -0.28]) (Table 6).
In patients who lost between 5-10% of baseline weight
(n =17, 29.3%) there was an improved GGT, alkaline
phosphatase, Forns index, and APRI (Table 6).
In patients from NGLCD group who have lost more
than 10% of the body weight (n = 6) there was a signifi-
cant improvement of non-invasive index of liver fibrosis
(Forns index) (Table 6).In LFD patients group
In patients with weight gain (n = 4, 7.7%) we observed a
slight improvement of Forns index, probably obtained in
the context of reduced fat consumption (Table 7).
In those with less than 5% loss of baseline weight (n = 31,
59.6%) we found improvements in AST, ALT, total biliru-
bin, INR, Forns index, APRI (Table 7).
In patients with 5-10% loss of baseline weight (n = 16,
30.8%) we found significant improvements in GGT and
Forns index, with an improvement in the remaining pa-
rameters, but it was not statistically significant (Table 7).Table 6 Groups of weight loss and liver function parameters
Weight gain 1-5% weight los
Mean SD Mean SD
PA (min/week) Baseline 17.0 3.9 27.5 16.
12-months 46.0 21.0 74.1 39.
Weight (kg) Baseline 85.4 15.0 85.8 15.
12-months 86.5 14.5 83.6 14.
BMI (kg/m2) Baseline 28.7 3.8 29.6 3.1
12-months 29.1 3.6 28.9 3.0
AST (IU/l) Baseline 44.8 25.0 51.8 31.
12-months 35.1 17.9 46.3 22.
ALT (IU/l) Baseline 41.5 24.9 68.7 42.
12-months 31.5 14.5 53.6 28.
Albumin (g/dl) Baseline 4.4 0.5 4.3 0.3
12-months 4.3 0.3 4.4 0.4
Bi (g/dl) Baseline 0.6 0.3 0.7 0.2
12-months 0.6 0.3 0.6 0.2
GGT (IU/l) Baseline 36.4 23.7 58.4 31.
12-months 30.8 19.2 51.9 34.
AST/ALT Baseline 1.2 0.4 0.8 0.3
12-months 1.1 0.2 0.9 0.2
FI Baseline 5.5 0.7 5.8 1.2
12-months 5.3 0.5 5.6 1.1
APRI Baseline 0.6 0.4 0.7 0.5
12-months 0.5 0.3 0.6 0.4
NGLCD normoglucidic low-calorie diet, PA physical activity, BMI body mass index,
GGT gamma-glutamyl transpeptidase, AST/ALT aspartate aminotransferase/alanine amiSteatosis
Fatty liver disease is common in patients with CHC. In our
study 52.7% patients (n = 58) presented hepatic steatosis,
60.3% (n = 35) patients in NGLCD group and 46.2%
(n = 24) patients in LFD group (p = 0.097).
The two diets were associated with reduction of both
prevalence and severity of steatosis (all p < 0.001) with-
out significant differences between groups; in NGLCD
group - mild: 68.6% vs. 77.4%, moderate: 25.7% vs. 22.6%,
severe: 5.7% vs. 0%; in LFD group - mild: 58.3% vs. 76.2%,
moderate: 29.2% vs. 23.8%, severe: 12.5% vs. 0%.
This reduction in prevalence and severity of liver
steatosis resulted in a significant diminution of serum
triglycerides in NGLCD and of serum ALT levels in LFD
group (p = 0.045, respectively p = 0.03). Such regression of
steatosis occurred even in absence of weight normalization.
Effects of diet programs on metabolic syndrome
parameters and fasting lipid profiles
At baseline, metabolic syndrome (≥3 criteria) was present
in 62.1% (n = 36) patients in NGLCD and in 61.5% (n = 32)
patients in LFD (p = 0.55). At 12 months, all parametersin patients with NGLCD
s 5-10% weight loss Weight loss >10% p
Mean SD Mean SD
2 34.4 23.6 28.7 20.8 0.310
7 106.2 40.7 114.5 26.6 0.002
1 82.9 11.1 77.9 6.7 0.592
7 76.4 10.7 67.7 6.2 0.024
30.4 4.6 27.2 0.8 0.295
28.0 4.5 23.6 0.6 0.011
7 61.8 45.2 32.3 16.9 0.336
4 51.9 36.4 35.7 12.5 0.460
0 61.3 44.9 35.2 26.7 0.213
0 54.9 31.4 34.2 19.2 0.168
4.2 0.4 4.4 0.3 0.430
4.4 0.4 4.5 0.2 0.744
0.6 0.2 0.6 0.1 0.566
0.6 0.2 0.6 0.1 0.653
1 59.4 47.8 39.3 26.1 0.403
2 46.9 29.3 24.3 8.0 0.152
1.1 0.5 1.1 0.5 0.050
1.0 0.3 1.2 0.5 0.075
5.6 1.2 4.6 0.5 0.160
5.4 1.3 4.3 0.5 0.086
0.9 0.8 0.4 0.2 0.419
0.7 0.6 0.4 0.2 0.596
AST aspartate aminotransferase, ALT alanine aminotransferase, Bi bilirubin,
notransferase ratio, FI Forns fibrosis index, APRI AST to platelet ratio index.
Table 7 Groups of weight loss and liver function parameters in patients with LFD
Weight gain 1-5% weight loss 5-10% weight loss Weight loss >10% p
Mean SD Mean SD Mean SD Mean SD
PA (min/week) Baseline 19.5 7.1 30.5 19.0 31.2 22.2 15.0 . 0.620
12-months 33.8 11.1 71.5 36.6 70.6 34.5 85.0 . 0.229
Weight (kg) Baseline 88.9 15.4 82.8 11.0 81.2 10.5 96.0 . 0.412
12-months 90.3 15.2 80.8 11.1 75.2 10.3 84.0 . 0.090
BMI (kg/m2) Baseline 30.4 4.1 29.2 3.2 29.5 3.9 32.4 . 0.774
12-months 30.9 4.1 28.5 3.2 27.4 3.8 28.4 . 0.334
AST (IU/l) Baseline 61.5 56.2 60.0 35.3 65.1 33.0 48.0 . 0.950
12-months 63.7 57.8 50.3 31.5 55.7 31.0 36.0 . 0.811
ALT (IU/l) Baseline 63.3 43.4 74.0 44.6 73.2 39.5 69.0 . 0.972
12-months 77.1 72.9 56.0 40.3 67.8 41.0 42.0 . 0.671
Albumin (g/dl) Baseline 4.3 0.5 4.2 0.5 4.3 0.4 3.8 . 0.692
12-months 4.4 0.3 4.3 0.3 4.4 0.3 3.7 . 0.186
Bi (g/dl) Baseline 0.7 0.2 0.7 0.3 0.6 0.2 0.8 . 0.579
12-months 0.7 0.1 0.7 0.2 0.6 0.2 0.6 . 0.514
GGT (IU/l) Baseline 71.3 55.5 59.9 28.0 73.1 36.3 55.0 . 0.592
12-months 67.5 67.5 48.5 26.6 57.3 34.5 46.0 . 0.654
AST/ALT Baseline 0.9 0.2 0.9 0.3 1.0 0.4 0.7 . 0.763
12-months 0.9 0.2 1.0 0.2 0.9 0.2 0.9 . 0.424
FI Baseline 5.4 1.7 5.6 1.4 5.7 1.3 4.6 . 0.863
12-months 5.2 1.8 5.3 1.4 5.5 1.3 4.6 . 0.904
APRI Baseline 0.7 0.6 0.8 0.6 0.8 0.5 0.3 . 0.866
12-months 0.7 0.6 0.6 0.6 0.7 0.4 0.3 . 0.887
LFD low fat diet, PA physical activity, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, Bi bilirubin, GGT gamma-glutamyl
transpeptidase, AST/ALT aspartate aminotransferase/alanine aminotransferase ratio, FI Forns fibrosis index, APRI AST to platelet ratio index.
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groups (all p < 0.005). At 12-months only 25.9% (n = 15)
form patients receiving NGLCD and 26.9% (n = 14) form
patients receiving LFD showed MetS; we did not find differ-
ences between groups at baseline and 12 months (Table 3).
Effects of diet programs on renal profile
There were no differences between the two diets regard-
ing the changes in renal function (eGFR, creatinin, urea).
In both groups, there were no associations between the
changes in protein intake (g/day) and the change in eGFR
(r = 0.04, p = 0.29) or creatinin (r = 0.07, p = 0.34).
Discussion
This RCT demonstrated the benefits of both normoglucidic
low-calorie and low-fat diets in individuals with CHC. Our
results indicated that after 1 year, overweight and obese
patients with CHC had similar weight reduction with
both diets. The dropout rate in LFD was significantly
greater than that in NGLCD. Similar to prior studies,
we observed a faster weight loss after initiation of a
NGLCD and equivalent weight loss after 1 year [26].This study demonstrated that lifestyle changes (NGLCD
or LFD and physical activity) improved the anthropomet-
ric parameters, glucose parameters and lipid and liver pro-
files. Further improvement was noted in the results of
non-invasive liver fibrosis testing, as well as improvement
of the prevalence and severity of hepatic steatosis.
The prevalence of MetS in our study was higher than
previously published in Romania [27] and in Europe, most
likely because we included overweight patients (BMI over
25 kg/m2). At baseline 61.5% of patients belonging to
the NGLCD group and 61.5% to the LFD group presented
MetS. In the largest retrospective survey (239 HCV-
positive subjects) 16.7% had metabolic syndrome [28]. In
other studies [29,30], the prevalence of metabolic syn-
drome in chronic HCV-infected patients ranged from 4.1
to 44% [31].
Even the weight loss at 12 months wasn’t spectacular
(−3.9 [95% CI −4.8, -3.1]kg in NGLCD vs. −3.1 [95% CI
−3.8, -2.3]kg in LFD) there was a reduction in MetS
prevalence (25.9% in NGLCD group and 26.9% in LFD
group). In CHC patients lifestyle changes through med-
ical nutritional therapy and physical activity led to an
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lin resistance, lower blood glucose, lower triglycerides,
total serum cholesterol, LDL-C, increased HDL-C, re-
ducing systolic and diastolic blood pressure.
Modest weight loss of 5–10% body weight is known to
reduce insulin resistance in obese individuals [32].
In our study a normoglucidic low-calorie diet (with lim-
ited refined carbohydrates and sugar intake, and increased
fruits, vegetables and whole grains intake) was accompanied
by improvement in insulin resistance (HOMA-IR) lipid and
liver profile.
The metabolic changes induced by the low-fat, high
carbohydrate, high protein diet were associated with simi-
lar weight losses, improved lipid and glucose profiles,
however there were no adverse changes in renal function
parameters but the compliance to this diet was lower
(drop out rate was almost double).
Thus, even if macronutrient intake was different, there
were similar improvements in glycemia and insulin re-
sistance, indicating that in the context of tolerable diets
and weight loss, mild variations in nutrient fuels have
limited impact on glucose metabolism.
In overweight/obese patients with steatosis who subse-
quently lost weight, liver-related abnormalities improved
[33]. Although weight loss may be difficult to achieve
and sustain, the patients who did manage to lose weight
showed a reduction in steatosis and abnormal liver en-
zymes as well as improvement in liver fibrosis, despite
the persistence of the virus [34]. Lifestyle changes are
deemed to be additive to proper antiviral treatment sched-
ules, which remain the standard of care [31].
The effects of lifestyle changes on hepatic inflamma-
tion and fibrosis varied [35,36], only one study showed
significant improvement [36].
In patients with steatosis, lifestyle changes (diet and ex-
ercise) were associated with improvement of ALT levels
[35] and steatosis [35,36].
Recently a semiquantitative index used to assess steatosis
was validated against histology [37] and proved useful in
the specific setting of lifestyle interventions [38].
Limitations of the study are: we used non-invasive
methods to estimate steatosis and fibrosis in patients with
CHC, and these indices are less sensitive and specific in
these patients; the analysis and presentation of only de-
tailed food journals may bias the estimate of food intake;
recruited patients were overweight (BMI > 25 kg/m2) thus
the prevalence of MetS was higher.
At this point only lifestyle interventions can be rec-
ommended to improve metabolic syndrome and obesity
associated with chronic hepatitis C, but their effect on
treatment response and long term outcome requires
further study.
Moderate exercise is recommended for all persons with
hepatitis C who did not experience advanced cirrhosis orother metabolic complications [17,39,40]. In the present
study, changes in food intake and the increase of physical
activity were sustainable, associated with long-term meta-
bolic benefits. In some studies, patients with CHC who
participated in light or moderate exercise programs reported
an improvement in some symptoms such as nausea, fa-
tigue, depression and appetite [17,35,36].
An important issue related to long-term of dietary in-
terventions is that adherence decreases over time and
therefore achieving the treatment goals involves an individ-
ualized education program, structured and continuously
adapted to the socio-biological and family environment,
with patient’s involvement in his own treatment.
Long-term benefits can be confirmed only by large stud-
ies over a longer period of time, where the patient has
adopted the habit of an optimal lifestyle.
Conclusions
The present study establishes the benefits of the low-
calorie diet and low-fat diet in management of patients
with hepatitis C regarding improvement of insulin resist-
ance, steatosis and also liver fibrosis.
Overweight or obese patients with hepatitis C undergo-
ing a lifestyle intervention (specific dietary intervention
and physical activity) for 1-year had significant improve-
ments in body weight, lipid and hepatic profiles.
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